Aravive Inc

Aravive — Investor Presentation (October 2019)

24 slides from Aravive's investor presentation, Oct 3, 2019

  1. Slide 1: Aravive Corporate Presentation October 2019

    Aravive Corporate Presentation October 2019 © 2019 Aravive, Inc. Exhibit 99.1

  2. Slide 2: Important Information: Forward-Looking Statements

    Important Information Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally i

  3. Slide 3: AVB-500 Offers First and Potentially Best-In-Class Opportunity in Oncology and Fibrosis

    AVB-500 Offers First and Potentially Best-In-Class Opportunity in Oncology and Fibrosis © 2019 Aravive, Inc. Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology and fibrosis: metastasis and drug resistance AVB-500: high affinity decoy

  4. Slide 4: Robust Development Pipeline in Oncology and Fibrosis

    Robust Development Pipeline in Oncology and Fibrosis © 2019 Aravive, Inc. **Phase 1 was conducted in healthy volunteers, allowing any next AVB-500 study to be either a phase 1b or phase 2 study Expansion into additional oncology indications where pre-clinical and biological rationale is strong Indic

  5. Slide 5: AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance

    AXL Tyrosine Kinase Promotes Invasion, Metastasis, and Resistance AXL is a member of tyrosine kinases that include Tyro3, AXL, and Mer (TAMs) AXL is activated by a single ligand, growth arrest–specific 6 (GAS6); Mer and Tyro3 can be activated by GAS6 and Protein S 1 Upregulated in many cancers 2, AX

  6. Slide 6: GAS6/AXL Signaling Critical in Resistant Metastatic Ovarian Cancer

    GAS6/AXL Signaling Critical in Resistant Metastatic Ovarian Cancer AXL in 0% (0/10) of normal ovarian tissue AXL in 73% (219/297) ovarian tumor samples including low grade serous, endometroid and advanced stage tumors1 Preclinical in vitro 1,2,3 Inhibition decreases invasion/migration Preclinical in

  7. Slide 7: AVB-500 Inhibits AXL Signaling by Neutralizing GAS6, Sole Ligand for AXL

    AVB-500 Inhibits AXL Signaling by Neutralizing GAS6, Sole Ligand for AXL AXL-Fc protein engineered for very high affinity for GAS6 ~200 fold greater than native AXL Favorable safety and PK profile GAS6 not needed by normal tissue GLP preclinical studies demonstrate ≥ 30-fold safety margin (relative

  8. Slide 8: Attractive Drug Attributes

    Attractive Drug Attributes Biomarker driven clinical development to accelerate program Low toxicity and no anticipated drug-drug interactions facilitate combination studies (unlike small molecules) © 2019 Aravive, Inc. The ability to combine with common standards of care allows access to a large tot

  9. Slide 9: AVB-500 Demonstrates Tolerability & Proof-of-Mechanism in Phase 1 Trial

    Trial Design Dosed 42 Healthy Volunteers Two-dosing regimens: SAD portion consisting of 4 sequential dose escalation cohorts RD portion consisting of 4 single doses once weekly Primary objective to assess safety and tolerability Secondary objective to assess PK/PD and to establish proof-of-mechanism

  10. Slide 10: Key Eligibility Criteria

    Key Eligibility Criteria 1-3 prior lines Measurable disease Platinum free interval ≤ 6mo after most recent platinum-containing regimen Adenocarcinoma NOS, high grade endometroid adenocarcinoma, mixed epithelial (≥ 80% high grade serous), high grade serous, or undifferentiated carcinoma ECOG performa

  11. Slide 11: Distribution of Baseline Characteristics and Prognostic Factors

    Distribution of Baseline Characteristics and Prognostic Factors (NCT03639246) (Efficacy Population) Pac arm (n=6) PLD arm (n=6) Age, years median (min, max) 63.5 (55, 82) 66 (53, 81) Prior lines 1 0 3 (50) 2 5 (83) 2 (33) 3 1 (17) 1 (17) Platinum Free Interval > 3mo 4 (67) 4 (67) < 3mo 2 (33) 2 (33)

  12. Slide 12: First Cycle Safety Data for the First Patients

    First Cycle Safety Data for the First 12 Patients (NCT03639246) Number of Subjects With (Safety Population) AVB+Pac (n=6) AVB+PLD (n=7) AE 6 (100) 5 (71.4) SAE 0 0 Dose Limiting Toxicity 0 0 Related AE with G>3 0 0 N=3 had Grade 2 infusion reactions with AVB infusion. A premedication regimen (anti-H

  13. Slide 13: Best Response Determined by Investigator-Assessed RECIST 1.1 for First 12 Patients

    Best Response Determined by Investigator-Assessed RECIST 1.1 for First 12 Patients * 2 Progressive Disease patients (both in Pac arm) are not shown as CTs were not obtainable at time of progression AVB+Pac AVB+PLD Response Rate AVB+PLD = 33% AVB+Pac = 50% Overall = 42% Clinical Benefit = 58% Clinica

  14. Slide 14: Current Average Treatment Duration for Responders in First 2 Patients is 7 Months

    Current Average Treatment Duration for Responders in First 12 Patients is 7 Months 4/5 PRs still ongoing 2 of the 4 continue to receive chemo + AVB 2 of the 4 are currently receiving AVB alone (no more chemotherapy) AVB+Pac AVB+PLD partial response (PR) progressive disease (PD) Time on Treatment (da

  15. Slide 15: Response Rates for Standard of Care in Platinum Resistant Ovarian Cancer

    Response Rates for Standard of Care in Platinum Resistant Ovarian Cancer are Well-Established at ~11 % (10-15%) Primary References: (1) J Clin Oncol. 2007 Jul 1;25(19):2811-8 (2) J Clin Oncol. 2010 Jul 1;28(19):3107-14 (3) J Clin Oncol. 2012 Nov 1;30(31):3841-7 (4) J Clin Oncol. 2013 Dec 10;31(35):4

  16. Slide 16: Conclusions Based on Available Data from the First Patients

    Conclusions Based on Available Data from the First 12 Patients AVB500 effectively sequesters serum GAS6, the sole ligand for AXL, in platinum-resistant ovarian cancer patients AVB500 administration not associated with any dose-limiting toxicities nor serious adverse events Infusion reactions mitigat

  17. Slide 17: Data not mature beyond the initial patients; mature data anticipated end of the year

    Data not mature beyond the initial 12 patients; mature data anticipated end of the year AVB-500 continues to be well tolerated Current response rates correlate with drug exposure: Peak and trough levels after first dose of AVB-500 predict anti-tumor activity Peak drug level correlates with response

  18. Slide 18: Drug Exposure-Response Relationship in Initial Patients

    Drug Exposure-Response Relationship in Initial 28 Patients Cmax C1D1.1 Trough C1D15 AVB-500 Concentration (mg/L) AVB-500 Concentration (mg/L) PD = progressive disease SD = stable disease PR = partial response © 2019 Aravive, Inc.

  19. Slide 19: Platinum Resistant Ovarian Cancer Data from Additional Doses Anticipated Middle of 2020

    Platinum Resistant Ovarian Cancer © 2019 Aravive, Inc. Data from Additional Doses (15 and 20mg/kg) Anticipated Middle of 2020 Data will inform regulatory strategy; company will explore potential for accelerated approval with FDA if exposure-response relationship and efficacy signal confirmed Randomi

  20. Slide 20: Robust Development Pipeline in Oncology and Fibrosis

    Robust Development Pipeline in Oncology and Fibrosis © 2019 Aravive, Inc. **Phase 1 was conducted in healthy volunteers, allowing any next AVB-500 study to be either a phase 1b or phase 2 study Expansion into additional oncology indications where pre-clinical and biological rationale is strong Indic

  21. Slide 21: Experienced, Methodical, Efficient Development Execution

    Experienced, Methodical, Efficient Development Execution Strong Clinical Development Team Dev Plan Enabled Bifurcated Strategy- Oncology and Fibrosis 4Q 2017- IND filed 1Q 2018- FIH in NHV initiated 2Q 2018- POM in NHV 3Q 2018- Tolerability in NHV 4Q 2018- P1b in Ovarian Cancer initiated 2Q 2019- PO

  22. Slide 22: Financials and Capitalization

    Financials and Capitalization NASDAQ: ARAV; Shares Outstanding*: 11.3M basic © 2019 Aravive, Inc. * As of June 30, 2019 Cash and cash equivalents*: $48.4M Cash and cash equivalents expected to enable the company to fund its operating plans through 2020

  23. Slide 23: AVB-500 Offers First and Potentially Best-In-Class Opportunity in Oncology and Fibrosis

    AVB-500 Offers First and Potentially Best-In-Class Opportunity in Oncology and Fibrosis © 2019 Aravive, Inc. Uniquely positioned in competitive landscape Robust pipeline addressing significant drivers of mortality in oncology and fibrosis: metastasis and drug resistance AVB-500: high affinity decoy

  24. Slide 24: Thank You

    Thank You © 2019 Aravive, Inc.

Aravive — Investor Presentation (October 2019) on 6ix